期刊文献+

Visfatin基因过表达对PCOS模型大鼠血浆胆固醇代谢和肝胆固醇合成的影响 被引量:1

Effects of Visfatin gene Overexpression on Hepatic Cholesterol Metabolism and Expression of SREBP-2 Gene in Rats with Polycystic Ovarian Syndrome
下载PDF
导出
摘要 目的探讨内脂素(visfatin)对PCOS模型大鼠血浆胆固醇代谢和肝胆固醇合成的影响。方法采用SD清洁雌性大鼠注射脱氢表雄酮(DHEA)和胰岛素诱导建立PCOS模型(n=20),并以等量油剂代替DHEA为对照组(n=20),大鼠visfatin基因真核表达质粒和空质粒分别转染PCOS组和对照组,ELISA方法测定血浆visfatin水平;RT-PCR测定肝HMG-CoA还原酶和SREBP-2 mRNA表达的变化。结果 visfatin质粒注射72 h后较注射前:(1)血浆visfatin水平升高(P<0.05);(2)HMG-CoA还原酶mRNA及SREBP2 mRNA的表达较转染前均升高(P<0.05),正常大鼠visfatin基因真核表达质粒注射组HMG-CoA还原酶mRNA的表达较转染前升高(P<0.05)。结论 visfa-tin过表达可能在PCOS模型大鼠脂代谢中起调节作用。 Objective Objective To study the effects of visfatin gene overexpression on hepatic cholesterol metabolism and expression of SREBP-2 gene in rats with Polycystic Ovarian Syn- drome(pcos).Methods Rat model induced by subcutaneous injecting dehydroeplandrosterone (DHEA) and Insulin on the 42-day-old female SD rats were injected daily with DHEA for up to 28 days and rats in group 2 injected with oil at the same time. The control plasmid pcDNA3.1 (+) and recombinant plasmid pcDNA3.1-visfatin were transfected into rats in control group and Polycystic Ovarian Syndrome group. Serum level of visfatin in rats of both groups were deter- mined with ELISA method;The plasma cholesterol, hepatic HMG-CoA reductase and sterol regulatory element binding protein 2(SREBP-2) mRNA were evaluated by RT-PCR before and after transfection. Results The expression of the serum level of visfatin was significantly in- creased in after 3 d of pcDNA3.1-visfatin transfection than those in the control plasmid pcD- NA3.1 (+) rats(P〈0. 05);HMG-CoA reductase mRNA level and SREBP-2 level of group re- combinant plasmid pcDNA3.1-visfatin was significantly increased than that those in the control plasmid pcDNA3.1 (+) rats (P〈O. 05)and HMG-CoA reductase mRNA level of group NT was significantly increased than that those in the control plasmid pcDNA3.1 (+) rats (P〈O. 05).Con- clusion The transfection of visfatin plasmid was related on blood I ipid level in Rats with PCOS.
出处 《湖北民族学院学报(医学版)》 2013年第2期17-19,共3页 Journal of Hubei Minzu University(Medical Edition)
基金 深圳市宝安区区级科研项目(2010544)
关键词 内脂素 多囊卵巢综合征 HMG—CoA还原酶 SREBP-2 Visfatin PCOS H MG-CoA reductase SREBP-2
  • 相关文献

参考文献8

二级参考文献22

  • 1Srinivasan K, Viswanad B, Asrat L, et al. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat:a modelfor type 2 diabetes and pharmacological screening [J]. Pharmacol Res, 2005, 5(4) :313-320.
  • 2Samal B, Sun Y. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor [J]. Mol Cell Biol, 1994,14(2) : 1431-1437.
  • 3Ye J M, Doyle P J, Iglesias M A, et al. Peroxisome proliferators-activated receptor (PPAR)-ot activation lowersmuscle lipids and improves insulin sensitivity in high fat-fed rats:comparison with PPAR-Yactivation [J]. Diabetes, 2001, 50(2) :411-417.
  • 4Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin [ J ]. Science, 2005,307 (10) : 426-430.
  • 5Bemdt J, Kloting N, Kralisch S, et al. PLsma visfatin concentration and fat depot-specific mRNA expression in humans [J]. Diabetes, 2005,54(10) :2911-2916.
  • 6Sun G, Bishop J, Khalili S, et al. Serum visfatin concentrations are positively correlated with serum triacylglycerols and down-regulated by overfeeding in healthy young men [J]. Am J Clin Nutr, 2007,85(2) :399-404.
  • 7SHURRAW S,TONELLI M. Statins for treatment of dyslipidemia in chronic kidney disease[J]. Petit Dial Int, 2006,26 (5) :523-539.
  • 8BRADFORD R H,SHEAR C L, CHREMOS A N,et al. Expanded clinical evaluation of lovastatin (EXCEL) study resuits: I . Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia[J]. Arch Intern Med,1991,151(1):43-49.
  • 9KASISKE B L. Hyperlipidemia in patients with chronic renal disease[J]. Am J Kidney Dis, 1998,32(5 Suppl 3) :S142-156.
  • 10OKUDA S, OH Y, TSURUDA H, et al. Adriamycin-induced nephropathy as a model of chronic progressive glomerular disease[J]. Kidney Int, 1986,29(2) :502-510.

共引文献5

同被引文献7

  • 1Younossi, ZM. Nonalcoholic fatty liver disease in patients with type 2diabetes [J] . Clin Gastroenterol Hepatol, 2004, 2 (3) : 262-265.
  • 2Fukuhara A, Matsuda M,Nishizawa M, et al, Visfatin: a protein se-creted by visceral fat that mimics the effects of insulin [J] . Science,2005,307 (5708) : 426-430.
  • 3Kowalska I, Straczkowski M, Nikolajuk A, et al. Serum visfatin in rela-tion to insulin resistance and markers of hyperandrogenism in lean andobese women with polycystic ovary syndrome [J] . Hum Reprod, 2007,22(7) : 1824-1829.
  • 4Sun Q, Li L, Li R, et al. Overexpression of vis?atin/PBEF/Nampt al-ters whole-body insulin sensitivity and lipid profile in rats [J] . AnnMed, 2009, 41 (4) : 311-320.
  • 5Adams CM, Reitz J, De Brabander JK,et al. Cholesterol and 25 -hy-droxycholesterol inhibit activation of SREBPs by different mecha-nisms, both involving SCAP and Insigs [J] . J Biol Chem, 2004, 279(50) : 52772-52780.
  • 6Auguet T, Terra X,Porras JA,et al. Plasma visfatin levels and geneexpression in morbidly obese women with associated fatty liver disease[J] . Clin Biochem, 2013, 46 (3) : 202-208.
  • 7赵君利,张向阳,陈子江.多囊卵巢综合征中非酒精性脂肪肝患病情况及相关危险因素分析[J].宁夏医科大学学报,2012,34(1):37-41. 被引量:5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部